Antivirals for influenza: Historical perspectives and lessons learned

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 372-378

  Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Amantadine; Antiviral resistance; Influenza; Neuraminidase; Oseltamivir; Pathogenesis; Zanamivir

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; HUMAN; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VIRUS A; MIDDLE EAR DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION;

ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; VIRAL MATRIX PROTEINS;

EID: 33747156960     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.016     Document Type: Short Survey

References (87)

1. Abed Y., Goyette N., and Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 49 2 (2005) 556-559
2. Anderson S.G., Burnet F.M., de St. Groths F., McCrea J.F., and Stone J.D. Mucins and mucoids in relation to influenza virus action, VI. General discussion. Aust. J. Exp. Biol. Med. Sci. 26 (1948) 403-411
3. Barnett J., Cadman A., Gor D., Dempsey M., Walters M., Candlin A., Tisdale M., Morley P.J., Owens I.J., Fenton R.I., Lewis A.P., Claas E.C., Rimmelzwaan G.F., DeGroot R., and Osterhaus A.D.M.E. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44 1 (2000) 78-87
4. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
5. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 295
6. Burmeister W.P., Ruigrok R.W., and Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO Journal. 11 1 (1992) 49-56
7. Burnet F.M. Mucins and mucoids in relation to influenza virus action, III: inhibition of virus haemagglutination by glandular mucins. Aust J Exp Biol Med Sci 26 (1948) 371-379
8. Burnet F.M., McCrea J.F., and Anderson S.G. Mucin as substrate of enzyme action by viruses of the mumps influenza group. Nature 160 (1947) 404-405
9. Burnet F.M., and Stone J.D. The receptor-destroying enzyme of V. cholerae. Aust. J. Exp. Biol. Med. Sci. 25 (1947) 227-233
10. Calfee D.P., Peng A.W., Cass L., Lobo M., and Hayden F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43 7 (1999) 1616-1620
11. Carr J., Ives J., Kelly L., Lambkin R., Oxford J., Mendel D., Tai L., and Roberts N. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir. Res. 54 2 (2002) 79-88
12. Cochran K.W., Maassab H.F., Tsunoda A., and Berlin B.S. Studies on the antiviral activity of amantadine hydrochloride. Ann. N. Y. Acad. Sci. 130 (1965) 432-439
13. Colman P.M., Varghese J.N., and Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303 5912 (1983) 41-44
14. Davies W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Watts J.C., Wood T.R., Hermann E.C., and Hoffmann C.E. Antiviral activity of 1-adamantanamine (amantadine). Science 144 (1964) 862
15. de Jong M., Thanh T.T., Khanh T.H., Hien V.M., Smith G.J.D., Chau N., Cam B.V., Qui P.T., Ha D.Q., Guan Y., Peiris J.S., Hien T.T., and Farrar J. Oseltamivir resistance during treatment of influenza H5N1. N. Engl. J. Med. 353 25 (2005) 2667-2672
16. Douglas R.M., Moore B.W., Miles H.B., Davies L.M., Graham N.M., Ryan P., Worswick D.A., and Albrecht J.K. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 314 2 (1986) 65-70
17. Doyle W.J., Skoner D., Alper C.M., Allen G., Moody S.A., Seroky J., and Hayden F.G. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J. Infect. Dis. 177 (1998) 1260-1265
18. Englund J.A., Champlin R.E., Wyde P.R., Kantarjian H., Atmar R.L., Tarrand J.J., Yousuf H., Regnery H., Klimov A.I., Cox N., and Whimbey E. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26 6 (1998) 1418-1424
19. Ferguson N.M., Mallett S., Jackson H., Roberts N., and Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51 (2003) 977-990
20. Ferguson N.M., Cummings D.A.T., Cauchemez S., Fraser C., Riley S., Meeyai A., Iamsirithaworn S., and Burke D.S. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437 7056 (2005) 209-214
21. Fritz R.S., Hayden F.G., Calfee D.P., Cass L., Peng A.W., Alvord G., Strober W., and Straus S.E. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 180 (1999) 586-593
22. Gottschalk, A., 1958, Neuraminidase: its substrate and mode of action, in Advances in Enzymology, 20 edn, vol. XX F.F. Nord (Ed.) Interscience Publishers, Inc., London, pp. 135-146.
23. Govorkova E.A., Fang H.B., Tan M., and Webster R.G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 48 12 (2004) 4855-4863
24. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R., and Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178 5 (1998) 1257-1262
25. Hall C.B., Dolin R., Gala C.L., Markovitz D.M., Zhang Y.Q., Madore P.H., Disney F.A., Talpey W.B., Green J.L., Francis A.B., and Pichichero M.E. Children with influenza A infection: treatment with rimantadine. Pediatrics 80 2 (1987) 275-282
26. Halloran, M. E., Hayden, F. G., Yang, Y., Longini, I. M., & Monto, A. S. 2006, Antiviral effects on influenza viral transmission and pathogenicity: Observations from household-based trials, American Journal of Epidemiology, vol. In press.
27. Hay A.J. Amantadine and rimantadine-mechanisms. In: Richman D.D. (Ed). Antiviral Drug Resistance (1996), John Wiley & Sons Ltd. 43-58
28. Hayden F. Pandemic influenza-is an antiviral response realistic?. Pediatr. Infect. Dis. J. 23 11 (2004) S262-S269
29. Hayden F.G. Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. 18 Suppl. B (1986) 177-183
30. Hayden F.G. Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. 356 (2001) 1877-1884
31. Hayden F.G., Albrecht J.K., Kaiser D.L., and Gwaltney J.M.J. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N. Engl. J. Med. 314 2 (1986) 71-75
32. Hayden F.G., and Aoki F.Y. Amantadine, rimantadine and related agents. In: Yu V.L., et al. (Ed). Antimicrobial Therapy and Vaccines. second ed. vol. 2 (2005), ESun Technologies, LLC, Pittsburgh, PA 705-729
33. Hayden F.G., and Aoki F.Y. Influenza neuraminidase inhibitors. In: Yu V.L., et al. (Ed). Antimicrobial therapy and vaccines. second ed. vol. 2 (2005), ESun Technologies, LLC, Pittsburgh, PA 773-789
34. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., Small I., Dutkowski R., Ward P., and Carr J. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. J. Infect. Dis. 189 (2004) 440-449
35. Hayden F.G., Belshe R.B., Clover R.D., Hay A.J., Oakes M.G., and Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321 25 (1989) 1696-1702
36. Hayden F.G., Douglas R.G.J., and Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob. Agents Chemother. 18 4 (1980) 536-541
37. Hayden F.G., Fritz R.S., Lobo M., Alvord G., Strober W., and Straus S.E. Local and systemic cytokine responses during experimental human influenza A virus infection. J. Clin. Invest. 101 3 (1998) 643-649
38. Hayden F.G., Gubareva L.V., Monto A.S., Klein T., Elliott M., Hammond J., Sharp S., and Ossi M. Inhaled zanamivir for preventing influenza in families. N. Engl. J. Med. 343 18 (2000) 1282-1289
39. Hayden F.G., Gwaltney J.M.I., Van d.C.R.L., Adams K.F., and Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob. Agents Chemother. 19 2 (1981) 226-233
40. Hayden F.G., Hoffman H.E., and Spyker D.A. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother. 23 3 (1983) 458-464
41. Hayden F.G., Osterhaus A.D.M.E., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., and Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N. Engl. J. Med. 337 13 (1997) 874-879
42. Hayden F.G., Sperber S.J., Belshe R.B., Clover R.D., Hay A.J., and Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother. 35 9 (1991) 1741-1747
43. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., and Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275 4 (1996) 295-299
44. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R., Miller M., Kinnersley N., Mills R.G., Ward P., and Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA 282 13 (1999) 1240-1246
45. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 9 (2004) 1627-1630
46. Hien T.T., Liem N.T., Dung N.T., San L.T., Mai P.P., Chau N., Suu P.T., Dong V.C., Mai L.T.Q., Thi N.T., Khoa D.B., Phat P.L., Truong N.T., Long H.T., Tung C.V., Giang L.T., Tho N.D., Nga L.H., Tien N.T.K., San L.H., Tuan L.V., Dolecek C., Thayaparan T.T., de Jong M., Schultsz C., Cheng P., Lim W., and Horby P. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350 12 (2004) 1179-1188
47. Hirst G.K. Absorption of influenza hemagglutinins and virus by red blood cells. Journal of Experimental Medicine 76 (1942) 195-209
48. Ison M.G., Gnann Jr. J.W., Nagy-Agren S., Treanor J., Paya C., Steigbigel R., Elliott M., Weiss H.L., and Hayden F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8 (2003) 183-190
49. Ison M.G., Gubareva L.V., Atmar R.L., Treanor J., and Hayden F.G. Recovery of Drug-Resistant Influenza Virus from Immunocompromised Patients: A Case Series. The Journal of Infectious Diseases 193 6 (2006) 760-764
50. Jackson H.C., Roberts N., Wang Z., and Belshe R. Management of influenza. Use of new antivirals and resistance in perspective. Clin. Drug Invest. 20 6 (2000) 447-454
51. Kaiser L., Fritz R.S., Straus S.E., Gubareva L., and Hayden F.G. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J. Med. Virol. 64 (2001) 262-268
52. Kaiser L., Henry D., Flack N., Keene O., and Hayden F.G. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin. Infect. Dis. 30 (2000) 587-589
53. Kaiser L., Keene O.N., Hammond J., Elliott M., and Hayden F.G. Impact of zanamivir on antibiotics use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. 160 (2000) 3234-3240
54. Kim C.U., Lew W., and Williams M.A. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119 (1997) 681-690
55. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 9436 (2004) 759-765
56. Klimov A.I., Rocha E., Hayden F.G., Shult P.A., Roumillat L.F., and Cox N.J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 172 5 (1995) 1352-1355
57. Lavrov S.V., Eremkina E.I., Orlova T.G., Galegov G.A., Soloviev V.D., and Zhdanov V.M. Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature 217 5131 (1968) 856-857
58. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 7062 (2005) 1108
59. Leneva I.A., Goloubeva O., Fenton R.J., Tisdale M., and Webster R.G. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 45 4 (2001) 1216-1224
60. Longini Jr. I.M., Halloran M.E., Nizam A., and Yang Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 159 7 (2004) 623-633
61. Longini Jr. I.M., Nizam A., Xu S., Ungchusak K., Hanshaoworakul W., Cummings D.A.T., and Halloran M.E. Containing pandemic influenza at the source. Science 309 5737 (2005) 1083-1087
62. Mast E.E., Harmon M.W., Gravenstein S., Wu S.P., Arden N.H., Circo R., Tyszka G., Kendal A.P., and Davis J.P. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol. 134 9 (1991) 988-997
63. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., and Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78 22 (2004) 12665-12667
64. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., and Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47 7 (2003) 2264-2272
65. Meindl P., and Tuppy H. 2-deoxy-2,3-dehydroxialic acids I. Syntheses and properties of 2-deoxy, 3dehydro-N-acylneuraminic acids and their methyl esters. Monatsh. Chem 100 (1969) 1295-2306
66. Mishin V.P., Hayden F.G., and Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 11 (2005) 4515-4520
67. Monto A.S., Robinson D.P., Herlocher L., Hinson J.M., Elliott M., and Crisp A. Zanamivir in the prevention of influenza among healthy adults. JAMA 282 1 (1999) 31-36
68. Moscona A. Neuraminidase Inhibitors for Influenza. N. Engl. J. Med. 353 13 (2005) 1363-1373
69. NISN. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly. Epidemiol. Rec. 80 17 (2005) 156
70. Oxford J.S., and Logan I.S. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 226 (1970) 82-83
71. Peiris J.S., Yu W.C., Leung C.W., Ng W.F., Nicholls J.M., Ng T.K., Chan K.H., Lai S.T., Lim W.L., Yuen K.Y., and Guan Y. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363 (2004) 617-619
72. Palese P., and Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. Journal of General Virology 33 1 (1976) 159-163
73. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61 2 (1974) 397-410
74. Sabin A.B. Amantadine hydrochloride. Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA 200 11 (1967) 943-950
75. Sabin A.B. Amantadine and influenza: evaluation of conflicting reports. J. Infect. Dis. 138 4 (1978) 557-566
76. Schwab R.S., England A.C.J., Poskanzer D.C., and Young R.R. Amantadine in the treatment of Parkinson's disease. JAMA 19 7 (1969) 1168-1170
77. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., and Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. Journal of Infectious Diseases 188 (2003) 57-61
78. Stilianakis N.I., Perelson A.S., and Hayden F.G. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J. Infect. Dis. 177 (1998) 863-873
79. Sweet C., Hayden F.G., Jakeman K.J., Grambas S., and Hay A.J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J. Infect. Dis. 164 5 (1991) 969-972
80. Seto J.T., and Rott R. Functional significance of sialidase during influenza virus multiplication. Virology 30 1 (1966) 731-737
81. Tsunoda A., Maassab H.F., Cochran K.W., and Eveland W.C. Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride. Antimicrob. Agents Chemother. 5 (1965) 553-560
82. Varghese J.N., McKimm-Breschkin J.L., Caldwell J.B., Kortt A.A., and Colman P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14 3 (1992) 327-332
83. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van P.T., Smythe M.L., White H.F., and Oliver S.W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 6428 (1993) 418-423
84. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353 13 (2005) 1374-1385
85. Whitley R.J., Hayden F.G., Reisinger K., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 2 (2001) 127-133
86. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49 10 (2005) 4075-4084
87. Zambon M., and Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 49 (2001) 147-156